How likely are you to recommend Redeye to a friend or colleague?
1
2
3
4
5
6
7
8
9
10
Not likely
Very likely
Not likely
1
2
3
4
5
6
7
8
9
10
Very likely
Message received
Thanks again for rating us!
SEARCH
Cantargia: Closing in on a Licensing Deal?
RR
Richard Ramanius
Premium Plan required to unlock
Unlock companies to access
more high quality research.
Redeye updates its view on Cantargia following a period that has brought promising trial results and the initiation of several new clinical projects. We adjust our estimates and valuation based on new timelines and an updated WACC.